Literature DB >> 34227075

COVID-19 in celiac disease: a multicentric retrospective cohort study.

G Gasbarrini1, T Dionisi, G R Corazza, N Aronico, G Cammarota, G Ianiro, I De Vitis, M Candelli, F A Mancarella, S Simeoni, G Addolorato, F Bonvicini.   

Abstract

OBJECTIVE: Celiac disease (CD) is an autoimmune disorder, characterized by increased susceptibility to bacterial and viral infections. Therefore, the CD patients could be exposed to an increased risk of contracting SARS-CoV-2, a virus for which the WHO declared a pandemic status in March 2020. This study aims to investigate the incidence of SARS-CoV-2 infection in CD patients, to assess the impact of CD on the risk of contracting this virus. PATIENTS AND METHODS: This retrospective multicentric cohort study evaluated 542 celiac patients, who answered a questionnaire concerning both the underlying disease (adherence to the gluten-free diet, residual symptoms) and the possible SARS-CoV-2 infection (swab outcome, presence and characteristics of symptoms and type of treatment received), referring to the period between 20th January 2020 and 27th October 2020.
RESULTS: Five patients (0.92%) tested positive; of these, 2 were asymptomatic and 3 developed symptoms of COVID-19. The incidence of SARS-CoV-2 infection in CD patients was not significantly different from the general population. The ratio of positive/diagnostic swabs tends to be higher in CD patients than in the general population (IR: 0.15; 0.06; p=0.06), whereas the number of subjects who performed the swab in this group is significantly lower (IR: 0.06; 0.15; p<0.001).
CONCLUSIONS: Although CD patients are more susceptible to infections, the incidence of SARS-CoV-2 infection in our sample was not significantly different from the general population. However, the positive/diagnostic swabs ratio seems to be higher, probably also due to the lower number of patients tested.

Entities:  

Mesh:

Year:  2021        PMID: 34227075     DOI: 10.26355/eurrev_202106_26150

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  1 in total

Review 1.  Gastrointestinal, hepatic and pancreatic manifestations of COVID-19 in children.

Authors:  Francesco Pegoraro; Sandra Trapani; Giuseppe Indolfi
Journal:  Clin Res Hepatol Gastroenterol       Date:  2021-10-02       Impact factor: 3.189

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.